AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
Stocks · News reference
Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Entered Strategic Drug Discovery Collaboration, Licensing Agreement With Insitro To Use Advanced AI Systems To Identify Novel Drug Targets, Develop Therapeutics For MASH, Cardiomyopathies
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
AstraZeneca releases Phase 3 HICKORY trial data for efzimfotase alfa in hypophosphatasia (HPP), showing key secondary improvements.
Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times
TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencing
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.